Overview

• Specialist centers, including Charité in Berlin, have begun administering Lecanemab infusions after the drug’s September 1 market entry.
• Clinics report that many candidates still require updated MRI scans or other assessments before treatment can start.
• Deutsche Hirnstiftung president Kathrin Reetz cites complex eligibility checks as the reason for the gradual start and notes no known supply shortages.
• Experts at the DZNE estimate that only a very small share of Germany’s roughly 1.2 million people with Alzheimer’s will qualify for antibody therapy.
• The European Commission has also approved Donanemab, with availability expected only after several more months of preparation.